GE Healthcare IPO on hold as new deal takes spotlight
advertisement

GE Healthcare IPO on hold as new deal takes spotlight

por Thomas Dworetzky, Contributing Reporter | February 25, 2019
Business Affairs
GE chairman and CEO Larry Culp has said that in light of its just-announced deal with Danaher, the IPO for its healthcare division might be on hold.

“An IPO [for GE's healthcare unit] in 2019 looks unlikely at this point,” Culp told CNBC.

That's due to its present focus on the sale of the GE Life Sciences unit to Danaher, where it will become a standalone business combined with Danaher's Life Science, according to CNBC.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

That deal is worth $21.4 billion – $21 billion in cash and the assumption of some GE pension costs. That's good news for Wall Street; as of year-end 2018, pensions accounted for $21 billion of the company's $55 billion in industrial debt, CNBC reported.

But some reports that the healthcare IPO is not ever going to happen are erroneous, the news station advised.

Instead, it is just delayed because, Culp told CNBC's Morgan Brennan, “we are focused on completing the [Danaher] carve out – which is 15 percent of the $20 billion healthcare segment – and focused on managing the remaining core business.”

Despite the interest in doing a health unit IPO in order to let GE focus on its core businesses, the interest in the biopharma unit presented too good an opportunity to miss.

“IPO of healthcare was Plan A, but we got lots of inbound calls about this business and this is clearly a superior path,” Culp told CNBC’s David Faber.

The Danaher deal is a big help for GE's debt-cutting efforts, with CNBC stating that Cowen Research said in a note that the deal offered “a rich valuation that goes a long way toward GE’s debt reduction.”

Credit Suisse also weighed in, calling the sale of biopharma “a positive” and adding that, “under CEO Culp, GE has been accelerating its strategy to strengthen and deleverage the balance sheet.”

Culp sat atop Danaher as CEO and president from 2000 to 2014, joining the GE board in April, 2018, and becoming GE Chairman and CEO when he replaced John Flannery in October, 2018. In April, 2018, Danaher expressed interest it taking the GE Life Sciences unit, said CNBC, citing the Wall Street Journal.

In January, Culp was touting the healthcare unit sale in a post-earnings conference call after GE's above-expectations Q4 revenue was revealed on the call, when he stated, “we expect to monetize just up to under 50 percent of our healthcare business,” adding that the unit “continues to prepare for public company separation, and that is progressing very well," according to CNBC.

You Must Be Logged In To Post A Comment